Q-omics provides the consensus-scored TPM3P6 profile across patient tissues and cancer cell-line models. TPM3P6 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TPM3P6 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, TPM3P6 RNA expression shows 16,267 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, BLCA, and UVM as cancer lineages where TPM3P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPM3P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPM3P6 survival associations across molecular data types. TPM3P6 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPM3P6 RNA expression–survival associations across cancer types. High TPM3P6 expression shows unfavorable associations in ACC, CESC, LUSC, COAD and LIHC, but favorable associations in PRAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TPM3P6 RNA expression.
This table summarizes TPM3P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for TPM3P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPM3P6 shows higher tumor expression in BLCA, HNSC, STAD, LIHC, COAD and CHOL. The BLCA box plot shows higher TPM3P6 RNA expression in tumor versus normal tissue (log2 FC = +1.259, t-test p < 0.001).
This table shows molecular features associated with TPM3P6 in patient tissues and cancer cell lines. In patient samples, TPM3P6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
